Pharma companies are wary about how they communicate with patients through social media, but the FDA's 2011 draft guidance, "Responding to Unsolicited Requests for Off-Label Information About Prescription Drugs and Medical Devices," offers some valuable insight, writes Peter Pitts, president of the Center for Medicine in the Public Interest and a former associate commissioner at the FDA. Pitts advises companies to remember that the message is what is important to the FDA, not the medium, and he offers 10 insights into the agency's draft guidance.
10 lessons for using social media from a former FDA official
SmartBrief Job Listings for Health Care
|Senior Director, Biostatistics||
|Associate - Food and Drug||
Keller and Heckman LLP
|Senior Paralegal - Research & Development, and Medical||